Ian Karp | Senior Vice President , Investor Relations and Corporate Communications |
John Leonard | President and Chief Executive Officer |
David Lebwohl | Executive Vice President and Chief Medical Officer |
Laura Sepp-Lorenzino | Executive Vice President and Chief Scientific Officer |
Glenn Goddard | Executive Vice President and Chief Financial Officer |
Joon Lee | Truist Securities |
Maury Raycroft | Jefferies |
Dae Gon Ha | Stifel |
Gena Wang | Barclays |
Joseph Thome | Cowen and Company |
Swapnil Malekar | Piper Sandler |
Salveen Richter | Goldman Sachs |
Luca Issi | RBC Capital Markets |
Richard Law | Credit Suisse |
Greg Harrison | Bank of America |
Mani Foroohar | SVB Leerink |
Jay Olson | Oppenheimer & Co. |
Ry Forseth | Guggenheim Partners |
Kostas Biliouris | BMO Capital Markets |
Yanan Zhu | Wells Fargo |
Good morning. And welcome to the Intellia Therapeutics' Second Quarter 2022 Financial Results Conference Call. My name is Andrew and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.